Skip to contentP
Phio Pharmaceuticals Corp.
P
PHIOPhio Pharmaceuticals Corp. Q1 2021 · 10-Q
Revenue—
Net Income-$3.41M-$3.41MN/M vs Q1 2020 EPS Diluted-$0.32-$0.32N/M vs Q1 2020 Operating Income-$3,638,000N/M Operating Cash Flow-$3,266,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phio Pharmaceuticals Corp. · CIK 1533040 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,272,000N/M ended Mar 31, 2021 · filed May 13, 2021 · 43 d after period end